IFLTD1 Inhibitors
Chemical inhibitors of IFLTD1 can impede the protein's function through various molecular mechanisms, depending on the signaling pathways that govern its activity. Bisindolylmaleimide I, for instance, serves as a selective blocker of protein kinase C (PKC), which can inhibit IFLTD1 by preventing the phosphorylation events typically mediated by PKC. This action presupposes that IFLTD1's activity is modulated by PKC-related signals. Similarly, staurosporine, with its broad kinase inhibition spectrum, can suppress IFLTD1 by globally obstructing phosphorylation processes essential for the protein's functionality. LY294002 and wortmannin, both phosphoinositide 3-kinases (PI3K) inhibitors, can hinder IFLTD1 by blocking PI3K-dependent signaling pathways. These pathways might be instrumental for IFLTD1's role in membrane trafficking or signal transduction, integral to the protein's operations.
Further, PD98059 and U0126 target the MAPK/ERK pathway, a critical regulator of cell cycle and apoptosis, presuming that IFLTD1 is involved in these cellular events. By inhibiting MEK1/2, these chemicals can suppress IFLTD1's activity if it is regulated through the MAPK/ERK signaling. Similarly, SP600125, as a c-Jun N-terminal kinase (JNK) inhibitor, can disable IFLTD1 by interfering with the JNK signaling pathway, which might be implicated in the regulation of IFLTD1, especially concerning stress response. SB203580, by inhibiting p38 MAP kinase, can affect IFLTD1's activity if it is involved in pathways associated with the inflammatory response. Rapamycin, an mTOR inhibitor, can impede IFLTD1 by disrupting the mTOR signaling pathway, which plays a role in cell growth and proliferation. Y-27632, a ROCK inhibitor, can inhibit IFLTD1 by affecting cell shape and motility, providing IFLTD1 is involved in these processes. Lastly, gefitinib and triciribine target the EGFR and AKT/protein kinase B signaling pathways, respectively, which might be necessary for IFLTD1's function in cell survival, metabolism, and other regulatory mechanisms.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
This chemical is a potent and selective inhibitor of protein kinase C (PKC), which can inhibit IFLTD1 by hindering the phosphorylation process that PKC mediates, assuming that IFLTD1 function is dependent on PKC-related signaling. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a non-selective protein kinase inhibitor. It can inhibit IFLTD1 by broadly inhibiting the phosphorylation events that might be crucial for IFLTD1's activity, provided IFLTD1's function is regulated through phosphorylation by kinases targeted by staurosporine. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
This chemical is a phosphoinositide 3-kinases (PI3K) inhibitor. IFLTD1 can be inhibited by LY294002 if the protein's activity is reliant on PI3K signaling pathways for membrane trafficking or signal transduction. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that can inhibit IFLTD1 by blocking the PI3K-dependent signaling pathways, which may be crucial for IFLTD1's function, especially in pathways related to growth factor signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
As a MEK inhibitor, PD98059 can inhibit IFLTD1 by blocking the MAPK/ERK pathway, which could be involved in the regulation of IFLTD1, especially if IFLTD1 is involved in cell cycle control or apoptosis. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2 and can inhibit IFLTD1 by inhibiting the MAPK/ERK signaling pathway, assuming that IFLTD1 activity is regulated through this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK) and can inhibit IFLTD1 by affecting the JNK signaling pathway, which may be implicated in the regulation of IFLTD1, particularly if IFLTD1 has a role in stress response. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
This compound is a p38 MAP kinase inhibitor and may inhibit IFLTD1 by disrupting p38 MAPK signaling pathways, which could be involved in the inflammatory response regulation of IFLTD1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can inhibit IFLTD1 by interfering with the mTOR signaling pathway, which is important for cell growth and proliferation, processes that IFLTD1 may be a part of. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor that can inhibit IFLTD1 by inhibiting Rho-associated protein kinase, which could affect cell shape, motility, and possibly IFLTD1's activity if it is involved in these cellular processes. | ||||||